GLP-1 In The News… Again.

Each week more stories are published about the new weight loss drugs Ozempic, Wegovy, Mounjaro, Zepbound and others (GLP1 receptor agonists). The momentum to prescribe these drugs is continuing to grow. These four articles give varying perspectives on the impacts of these drugs.

Sharon Osbourne on her Experience using Ozempic

The message here is important. Her experience of becoming addicted to losing weight, highlights what can never be tested in a clinical trial. These drugs work by suppressing appetite and slowing digestion. The mental toll that takes has not been discussed until now.

Weight-Loss Drug Wegovy Slashes Risk of Death in Some People with Heart Disease and Wegovy's heart benefits due to more than weight loss, Novo says

Both of these articles highlight the recent findings that these drugs have health benefits outside of weight loss, specifically related to heart disease.

Do GLP-1 Receptor Agonists Improve Cardiovascular Health Independently of Weight Loss?

While this article from Dr. Peter Attia throws doubt on their claims by asking the question whether the cardiac benefits were because of or separate from the weight loss experienced. As he explains, the research thus far does not indicate that the drug (GLP-1) alone, absent excessive weight loss, has any positive effects on cardiovascular health.